Intellia Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Intellia Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Intellia Therapeutics Inc
Rating: 1.4263055
Author: Trendlyne DVM scores

Momentum Trap

about

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a rev...

11.26 -0.34 (-2.93%)

52.61% Fall from 52W High

778.4K

XNAS Volume

XNAS 29 Aug, 2025 10:24 AM (EDT)

Low Financial Strength

22.2 / 100

Expensive Valuation

15.0 / 100

Technically Neutral

54.7 / 100

Momentum Trap These stocks are the ones with poor quality and also financials and technical ranging from bad to medium score. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM

1Yr Price target upside is 207%

25 analysts

Intellia Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Intellia Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a rev...

52.61% Fall from 52W High

SWOT Analysis

Intellia Therapeutics Inc Live Price Chart